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Background: Metastasis to the breast from nonmammary malignancies is rare, and mostly involves patients in a
pre-terminal condition with systemic metastases outside the breast. Lymphoma and leukemia, melanoma, and lung
carcinoma are the most common primary malignancies to cause breast metastasis; metastasis of soft tissue sarcoma
to the breast is very rare. Here, we report a case of primary lower-extremity myxoid liposarcoma with the development
of a solitary metastasis to the breast. To the best of our knowledge, no isolated case reports of solitary breast metastasis
by myxoid liposarcoma have been previously reported in the English-language literature.
Case presentation: The patient, a 66-year-old woman, had been previously diagnosed with myxoid liposarcoma of
the right thigh. At 21 months after complete surgical resection of the primary tumor with negative margins, a
palpable tumor was identified in the patient’s left breast. Needle biopsy revealed the presence of metastatic
liposarcoma; positron emission tomography/computed tomography examination confirmed the metastasis as solitary,
and no local recurrence of the primary tumor was identified. The patient underwent lumpectomy with negative
margins and did not provide consent for adjuvant chemotherapy. As with the biopsy specimen and the total cleavage
specimen, myxoid liposarcoma with metastasis to the breast was diagnosed. No recurrence or new metastases were
observed five years after resection of the metastatic breast lesion.
Conclusions: We have presented an extremely rare case of a solitary metastatic breast tumor arising from myxoid
liposarcoma of the lower limbs. There is no standard treatment for the management of solitary breast metastasis from
myxoid liposarcoma. Therefore, treatment should be guided by consideration of an individual patient’s overall
condition.
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Breast metastases from nonmammary malignancies are
uncommon. Metastases of nonmammary malignancies to
the breast represents less than 2% of all breast tumors
[1-3]. According to a large recent survey of breast metasta-
ses, the most common primary malignancies to cause
breast metastasis are lymphoma and leukemia, melanoma,
and lung carcinoma; breast metastasis of soft tissue sar-
coma is relatively rare [3-5]. Breast metastasis usually indi-
cates disseminated metastatic disease and carries a poor
prognosis [2]. Typically, most patients are in a pre-terminal* Correspondence: masahiro@m3.kufm.kagoshima-u.ac.jp
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unless otherwise stated.condition with systemic metastases outside the breast
[2,3]. Here, we report an extremely rare case of primary
lower-extremity myxoid liposarcoma with development
of a solitary metastasis to the breast. Five years follow-
ing resection of the metastatic breast lesion, the patient
is without evidence of disease and has a good quality of
life.
In our review of the English scientific literature per-
taining to solitary breast metastasis arising from myxoid
liposarcoma, only two other cases have been reported to
date [6,7], but these cases provided either no clinical in-
formation [6] or insufficient clinical information [7].
This is the first isolated case report of solitary breast me-
tastasis from myxoid liposarcoma demonstrating clinical
findings, clinical management and prognosis. This caseal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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brief review of the literature relevant to surgeons.
Case presentation
A 66-year-old woman complained of a progressively en-
larging, painful mass over the lateral part of her right
thigh for the past 4 months. She had no medical history
of note. Magnetic resonance imaging (MRI) revealed a
large, well-defined mass located in the region from the
anterior to the posterior compartment of the right thigh
(Figure 1A, B). Positron emission tomography/computed
tomography (PET/CT) revealed significant accumulation
of the tracer (standardized uptake value (SUV) of 3.5) in
the lesion (Figure 1C). With the exception of the right
thigh, no significant accumulation was observed on
PET/CT. A biopsy of the mass suggested the presence of
a myxoid liposarcoma. After complete surgical resection
of the tumor with negative margins, histological exam-
ination confirmed the preoperative diagnosis of myxoid
liposarcoma (less than 5% round cell component [8,9])
(T2bN0M0G2 : stage IIB) (Figure 1D). Chemotherapy
was not administered.
At 21 months after surgical resection, the patient con-
sulted a local hospital after noticing a mass in her left
breast. She underwent a core needle biopsy. The patho-
logical diagnosis was metastatic liposarcoma, and the pa-
tient was subsequently referred to our hospital. On
physical examination, a well-circumscribed, mobile, 4 ×
3 cm mass was palpable at the 5 o’clock position, close
to the areolar border. There was no nipple discharge.
Ultrasonography demonstrated a 3.2 × 2.8 cm irregular,
hypoechoic, heterogeneous mass in the breast. Macro-
calcifications were not observed (Figure 2A). Axial
PET/CT fusion images revealed the accumulation to beFigure 1 Radiological images and histological findings of the primary
heterogeneous, ill-defined mass measuring 53 × 48 × 120 mm in the right t
slight, heterogeneous 18 F-fluorodeoxyglucose uptake in the tumor (SUV =
on PET/CT. (D) Microscopic examination of the resected specimen revealed
of mature lipoblasts. No round-cell components were found.comparatively high (SUV of 2.1) in the tumor within
the left breast (Figure 2B). With the exception of the
breast, accumulation suggestive of metastasis was not
found on PET/CT (Figure 2C). The patient underwent
partial mastectomy with negative margins (1 cm from
the edge of the tumor) and did not provide consent for
adjuvant chemotherapy. Macroscopically, the resected
tissue was a relatively well-circumscribed, multinodu-
lar, gelatinous tumor (Figure 3A); as with the biopsy
specimen and the hematoxylin and eosin stained total
cleavage specimen, metastatic liposarcoma was diagnosed
(Figure 3B, C).
The patient’s postoperative course was uneventful.
Since most sarcomas recur in the lungs, the patient has
been carefully observed with repeated total body CT im-
aging. No recurrence or new metastases in the lungs or
elsewhere were observed in the 5 years after resection of
the metastatic lesion in the breast.Discussion
Although the breast is the most common site of primary
cancer for women, metastatic lesions in the breast are
uncommon. Most metastatic breast lesions are metasta-
ses from the contralateral breast, but rare metastases
from primary malignancies outside the breast can occur
[1-4]. The rarity of this occurrence is suggested to be
due to the characteristics of breast tissue, as it contains
large areas of fibrous tissue with a relatively poor blood
supply [2]. This is particularly the case in older women,
whose breasts have more fibrous tissue and a poorer
blood supply compared with younger women [10]. This
anatomical difference also explains why the majority of
breast metastases occur in woman younger than 50 yearstumor. Axial (A) T1-weighted and (B) T2-weighted MRI showed a
high. (C) Maximum intensity projection PET imaging demonstrated
3.5) (red arrow). Accumulation suggestive of metastasis was not found
the typical appearance of a myxoid liposarcoma with a large number
Figure 2 Radiological images of metastatic breast tumor. (A) Ultrasonography demonstrated a 3.2 × 2.8 cm irregular, hypoechoic,
heterogeneous mass in the breast. Macrocalcifications were not observed. (B) Axial PET/CT fusion images revealed the accumulation to be
comparatively high (SUV of 2.1) in the tumor within the left breast. (C) With the exception of the breast, accumulation suggestive of metastasis
was not found on PET/CT.
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in women older than 50 years of age.
According to the literature, breast metastases occur
more frequently in malignant melanomas, sarcomas, lung
cancers, ovarian tumors, renal carcinomas, and thyroid
tumors [3,11,12]. Previous reports have suggested that
breast metastases from different primary tumors have dis-
tinct radiological patterns. For instance, the largest lesions
occurred in rhabdomyosarcomas, followed by hepatocellu-
lar carcinomas and squamous cell carcinomas of the head
and neck region. The smallest lesions occurred in thyroid
gland carcinomas [13]. Most breast metastases showed
circumscribed margins, while metastases from rhabdo-
myosarcomas were microlobulated [13]. On ultrasound,
breast lesions in lung cancers were usually inhomogen-
eously hypoechoic with circumscribed margins and dem-
onstrated posterior shadowing in almost 50% of the cases.
Breast metastases from ovarian carcinomas have typically
microlobulated margins and posterior enhancement [13].
Soft tissue sarcoma is a rare tumor that accounts for less
than 1% of all malignant neoplasms in humans. Myxoid
liposarcoma is the second most common subtype ofliposarcoma and represents approximately 10% of all
adult soft tissue sarcoma [8,9]. Approximately one-third
of patients with myxoid liposarcoma develop distant metas-
tasis, which carries a poor prognosis, and it is well docu-
mented that myxoid liposarcoma has an unusual metastatic
pattern. Myxoid liposarcoma tends to metastasize to extra-
pulmonary sites, such as soft tissue of the opposite side and
bone, without causing pulmonary metastases; in contrast,
most of the histological types of soft tissue sarcoma
metastasize hematogenously to the lungs [8,9].
Regarding metastasis to the breast, a few cases of breast
metastasis from myxoid liposarcoma have been reported
in the previous literature [6,7,14,15]. However, even with
myxoid liposarcoma, breast metastasis is mostly a result
of disseminated systemic metastasis outside the breast,
and solitary metastasis to the breast is extremely rare. To
the best of our knowledge, no isolated case reports of soli-
tary breast metastasis from myxoid liposarcoma have been
previously reported in the English-language literature. In
our review of publications written in English, we were
only able to identify two cases of solitary metastasis to the
breast from myxoid liposarcoma [6,7]. One report briefly
Figure 3 Macroscopic and histological findings of the excised specimen. (A) Gross appearance of the resected tissue: a relatively well-circumscribed,
multinodular, gelatinous tumor without bleeding or necrosis. The tumor was located in the breast tissue but was close to the pectoralis major muscle.
The surface of the pectoralis major muscle was partially resected with the tumor. (B) Microscopic examination of the resected specimen revealed the
presence of mammary gland tissue surrounding the tumor. (C) Lipoblasts were also seen in the resected breast tumor. Histological features of the
breast lesion were found to be identical to those of the primary lesion of the extremity. The Estrogen Receptor and Progesterone Receptor status of
the histological material was negative.
Yokouchi et al. BMC Cancer 2014, 14:482 Page 4 of 6
http://www.biomedcentral.com/1471-2407/14/482mentions the existence of breast metastases from myxoid
liposarcoma without any information about the patient
[6]. The other report described solitary metastasis to the
breast from myxoid liposarcoma of the thigh developing
four years after the primary diagnosis [7]. However, the
age, gender, radiological and pathological findings, treat-
ment strategy and prognosis of the patients were not de-
scribed [7]. The characteristics and treatment strategies of
solitary breast metastasis from myxoid liposarcoma have
not been fully ascertained.
At present, conservative treatment with the systemic
administration of anticancer agents in conjunction with
radiation therapy is often chosen to treat metastatic le-
sions, and the necessity of surgical treatment remains
controversial. As previously mentioned, breast metasta-
sis usually indicates disseminated metastatic disease and
a poor prognosis [2,16]. Yeh et al. reported that, in their
series, over 90% of breast metastases were associatedwith disseminated metastatic disease, with most patients
dying within a year of the diagnosis of breast metastasis;
the median survival was 4 months in this study [2].
Amichetti et al. also described the development of breast
metastasis as a negative prognostic factor, and they con-
cluded that recognition of breast metastasis is useful in
avoiding unnecessary radical operative procedures [16].
In general, metastatic tumors usually require treat-
ment according to the origin and type of the tumor. Re-
garding myxoid liposarcoma, the disease-free interval
and the overall survival rate have been shown to be sig-
nificantly better for patients with extrapulmonary metas-
tases compared with those with pulmonary metastases
[6,7]. Spillance et al. analyzed the natural history of soft
tissue metastasis from myxoid liposarcoma and con-
cluded that soft tissue metastases should be managed ag-
gressively, most often involving further surgery [17]. The
impact of chemotherapy on patients with metastatic
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the present case, we decided to perform surgical treatment.
There is no consensus regarding the treatment of solitary
breast metastasis from myxoid liposarcoma, so clinical de-
cisions must be formulated on a case-by-case basis. As a
result of surgical treatment, our patient is alive with no evi-
dence of disease five years after resection of the metastatic
breast lesion. Curative surgical resection appears to have
been an effective treatment choice in this case.
Regarding radiotherapy, myxoid liposarcoma is known
to be particularly sensitive to radiotherapy compared
with other histologic subtypes of soft tissue sarcoma
[18]. Therefore, radiotherapy has been widely used in
combination with surgery for cases in which adequate
surgical resection is not feasible. Because of the rarity of
the clinical scenario in our case, it is difficult to com-
pare the validity of the resection that we performed for
the metastatic lesion with radiation therapy as a local
therapy. More cases are required in order to identify the
ideal treatment protocol for solitary breast metastasis
from myxoid liposarcoma.
PET/CT is widely used for staging in various malignan-
cies, especially for nodal and distant metastasis staging. In
general, sarcomas tend to be 18 F-fluorodeoxyglucose avid
and whole-body PET/CT is described as an ideal modality
for staging malignant soft tissue sarcomas [9]. However,
several recent studies have reported wide-ranging sensitiv-
ities and specificities for this method of detection of meta-
static soft tissue sarcoma [19]. Although we used PET/CT
in the preoperative evaluation of this patient, the utility
of PET/CT for the staging of soft tissue sarcoma re-
mains to be defined [19].
Concerning the concept of multicentric liposarcoma
[9], debate still persists as to whether multifocal myxoid
liposarcoma represents metastatic disease or independ-
ently arising, multicentric primary disease. To formulate
an optimal treatment plan for patients, it might be im-
portant for a clinician to distinguish between metastasis
and multicentric primary disease. While in the future it
may be possible to make this distinction by molecular
analysis of the tumor [20], at present the most plausible
explanation for the overwhelming majority of cases of
multifocal myxoid liposarcoma is metastatic disease [9].Conclusions
We have presented an extremely rare case of a solitary
metastatic breast tumor arising from myxoid liposarcoma
of the lower limbs. Although treatment experience is lim-
ited owing to the rarity of this condition, our case report
illustrates that, depending on a patient’s overall condition,
complete curative resection might be considered a valid
therapeutic option when treating myxoid liposarcoma
with breast metastasis.Ethical adherence
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